Solara Active Pharma Sciences Ltd Share Price Target From 2025 to 2030

Solara Active Pharma Sciences Ltd, a leading player in the Active Pharmaceutical Ingredients (API) segment, has been making strong strides in the pharma sector. The company specializes in niche APIs and has a global presence in regulated markets. With consistent R&D investments and strategic collaborations, Solara is emerging as a strong growth stock in the healthcare space. In this article, we will explore Solara’s share price targets from 2025 to 2030, along with detailed investment insights.

Solara Active Pharma Share Price Today (As of May 2025)

About Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd is a specialty pharmaceutical company focused on the research, manufacturing, and commercialization of APIs. Headquartered in India, it serves several global markets and has gained recognition for its quality and compliance with international regulatory standards.

The company continues to expand its product portfolio, strengthen its R&D capabilities, and target niche therapeutic segments where margins are higher.

Key Highlights:

• Strong presence in API manufacturing with exports to regulated markets

• Expanding pipeline of niche and high-value APIs

• Strong compliance with USFDA and European regulatory bodies

• Focused on sustainable operations and cost efficiency

• Book Value of ₹245.77 indicates strong fundamentals

Solara Active Pharma Shareholding Pattern (March 2025)

This balanced shareholding pattern shows strong promoter commitment, healthy foreign institutional backing, and wide retail participation.

Solara Active Pharma Share Price Target 2025 to 2030

These projections are based on industry growth trends, Solara’s R&D initiatives, and expansion into regulated markets.

Year-Wise Analysis & Investment Advice

Solara Active Pharma Share Price Target 2025: ₹650 – ₹700

By 2025, Solara is expected to stabilize as demand for niche APIs increases globally.
Why?

• Growing exports to the US and Europe

• Rising demand for specialty APIs in India

• Improving operational efficiency

Investment Advice: Investors may consider accumulating the stock on dips for medium-term growth.

Solara Active Pharma Share Price Target 2026: ₹720 – ₹820

In 2026, revenue growth is likely to be supported by strong exports.
Why?

• New product launches in regulated markets

• Increased market share in therapeutic APIs

• Partnerships with global pharma companies

Investment Advice: Hold for long-term; expect steady growth.

Solara Active Pharma Share Price Target 2027: ₹850 – ₹950

By 2027, Solara’s growth could accelerate with improved earnings visibility.
Why?

• Expansion of R&D pipeline

• Cost advantages from economies of scale

• Better product mix improving margins

Investment Advice: Long-term investors should reinvest dividends for compounding.

Solara Active Pharma Share Price Target 2028: ₹1,000 – ₹1,150

Solara may cross the ₹1,000 mark by 2028.
Why?

• Growing penetration in global pharma markets

• Higher capacity utilization at plants

• Strong balance sheet with reduced debt

Investment Advice: Continue to hold; attractive CAGR potential.

Solara Active Pharma Share Price Target 2029: ₹1,200 – ₹1,400

Steady growth in global APIs demand may fuel higher valuations.
Why?

• Increased API demand from generic manufacturers

• Expanding presence in emerging markets

• Consistent improvement in EPS and ROE

Investment Advice: Good stock for long-term portfolios.

Solara Active Pharma Share Price Target 2030: ₹1,500 – ₹1,750

By 2030, Solara may regain strong momentum closer to its all-time high.
Why?

• Leadership in niche APIs

• Strong promoter and institutional backing

• Enhanced profitability and global expansion

Investment Advice: Excellent choice for long-term investors aiming for wealth creation.

Should You Invest in Solara Active Pharma for the Long Term?

Yes, Solara Active Pharma Sciences Ltd offers a strong long-term story backed by its leadership in the API segment, global presence, and consistent R&D investments.

Key Reasons to Invest:

• Strong presence in regulated pharma markets

• Diversified API portfolio with niche focus

• Strong book value per share (₹245.77)

• Increasing institutional support

Risks to Watch Out For:

• High competition in global API market

• Regulatory risks in exports

• Price volatility due to global demand fluctuations

Conclusion

Solara Active Pharma Sciences Ltd is fundamentally strong, with consistent growth potential in the pharmaceutical API segment. Its expanding pipeline, global presence, and improving fundamentals make it a promising stock for long-term investors.

Currently, the share price is around ₹639, and analysts expect it could reach between ₹1,500 and ₹1,750 by 2030. Investors looking for a high-growth pharma stock can consider Solara Active Pharma as a solid long-term bet.

Frequently Asked Questions (FAQs) about Solara Active Pharma Sciences Ltd

1. What is the current share price of Solara Active Pharma?
As of May 2025, Solara’s share price is around ₹639.

2. What is the share price target for Solara in 2025?
The expected 2025 target is between ₹650 and ₹700.

3. What is Solara’s 2030 target price?
By 2030, Solara’s share price could reach between ₹1,500 and ₹1,750.

4. Is Solara Active Pharma a good long-term investment?
Yes, due to its strong API business model, global presence, and consistent R&D.

5. What is Solara’s 52-week high and low?
52-week high is ₹882.80, while 52-week low is ₹442.80.

6. What is the promoter holding in Solara Active Pharma?
Promoters hold 42.01% of the shares.

7. Does Solara export APIs globally?
Yes, Solara exports to the US, Europe, and other regulated markets.

8. What is Solara’s all-time high?
The all-time high is ₹1,859.95.

9. Is Solara a dividend-paying company?
Dividend payments vary based on yearly performance, but the focus remains on reinvestment in growth.

10. Should retail investors buy Solara shares now?
Yes, retail investors can consider buying in phases for long-term gains.

???? Disclaimer: This article is for educational purposes only. Please consult a SEBI-registered financial advisor before investing.